Semagacestat for treatment of Alzheimer's disease [1]

New England Journal of Medicine

Volumn 369, Issue 17, 2013, Pages 1660-1661

  Gupta, Veer B ^a   Gupta, Vivek K ^b   Martins, Ralph ^a  

^a EDITH COWAN UNIVERSITY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GAMMA SECRETASE; HERMES ANTIGEN; NOTCH RECEPTOR; PROTEIN TYROSINE KINASE; SEMAGACESTAT; UVOMORULIN; ALANINE; AZEPINE DERIVATIVE; DRUG DERIVATIVE; SECRETASE;

ALZHEIMER DISEASE; CHRONIC LYMPHATIC LEUKEMIA; ENZYME INHIBITION; HUMAN; LETTER; LYMPHOCYTE ACTIVATION; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SKIN CANCER; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; FEMALE; MALE; NOTE;

ALANINE; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; AZEPINES; FEMALE; HUMANS; MALE;

EID: 84886285667     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1310845     Document Type: Letter

References (5)

1. Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013;369:341-50.
2. Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol 2002;3:673-84.
3. Zhang S, Wu CC, Fecteau JF, et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A 2013;110:6127-32.
4. Settleman J. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin. Cancer Cell 2009;16:278-9.
5. van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008;65:3756-88.